AK Medical Holdings Limited carried out a repurchase of 50,000 ordinary shares on 25 September 2026, paying a volume-weighted average price of HK$4.735 per share. The transaction totalled HK$0.24 million.

Following the buyback, the company’s issued share capital (excluding treasury shares) slipped to 1.08 billion shares from 1.08 billion, representing a 0.0046% reduction. Concurrently, the treasury-share balance rose to 32.67 million shares, bringing total shares in issue (including treasury stock) to 1.11 billion.

The purchase forms part of the repurchase mandate approved on 17 June 2026, which authorises the company to acquire up to 112.46 million shares. Cumulative repurchases under this mandate now stand at 48.24 million shares—equivalent to 4.29% of the company’s issued share base at the mandate date—leaving capacity for a further 64.23 million shares.

In accordance with Hong Kong Stock Exchange rules, AK Medical is subject to a moratorium on issuing new shares or disposing of treasury shares until 25 October 2026. The board has confirmed that the transaction complied with all applicable regulatory requirements and that payment for the repurchased shares has been fully settled.